scholarly journals Delineation of atypical insulin receptors from classical insulin and type I insulin-like growth factor receptors in human placenta

1989 ◽  
Vol 257 (1) ◽  
pp. 101-107 ◽  
Author(s):  
H A Jonas ◽  
A J Cox ◽  
L C Harrison
Keyword(s):  
Growth Factor ◽  
Insulin Receptor ◽  
Human Placenta ◽  
Insulin Receptors ◽  
Type I ◽  
Insulin Like Growth Factor ◽  
Binding Properties ◽  
High Affinity ◽  
Igf Receptors ◽  
Placental Membranes

Insulin-like growth factor (IGF)-binding sites copurifying with human placental insulin receptors during insulin-affinity chromatography consist of two immunologically distinct populations. One reacts with monoclonal antibody alpha IR-3, but not with antibodies to the insulin receptor, and represents Type I IGF receptors; the other reacts only with antibodies to the insulin receptor and is precipitated with a polyclonal receptor antibody (B-10) after labelling with 125I-multiplication-stimulating activity (MSA, rat IGF-II). The latter is a unique sub-population of atypical insulin receptors which differ from classical insulin receptors by their unusually high affinity for MSA (Ka = 2 x 10(9) M-1 compared with 5 x 10(7) M-1) and relative potencies for insulin, MSA and IGF-I (40:5:1 compared with 150:4:1). They represent 10-20% of the total insulin receptor population and account for 25-50% of the 125I-MSA binding activity in Triton-solubilized placental membranes. Although atypical and classical insulin receptors are distinct, their immunological properties are very similar, as are their binding properties in response to dithiothreitol, storage at -20 degrees C and neuraminidase digestion. We conclude that atypical insulin receptors with moderately high affinity for IGFs co-exist with classical insulin receptors and Type I IGF receptors in human placenta. They provide an explanation for the unusual IGF-II binding properties of human placental membranes and may have a specific role in placental growth and/or function.

scholarly journals Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity

1993 ◽  
Vol 290 (2) ◽  
pp. 419-426 ◽  
Author(s):  
M A Soos ◽  
C E Field ◽  
K Siddle
Keyword(s):  
Monoclonal Antibody ◽  
Growth Factor ◽  
Insulin Receptors ◽  
Beta Subunit ◽  
Type I ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf Receptors ◽  
Igf I ◽  
Growth Factor I

Hybrid insulin/insulin-like growth factor-I (IGF-I) receptors have previously been described in human placenta, but it has not been possible to study their properties in the presence of classical insulin receptors and type I IGF receptors. To facilitate the purification of hybrids, we produced an anti-peptide monoclonal antibody IGFR 1-2, directed against the C-terminal peptide of the type I IGF receptor beta-subunit. The antibody bound native human and rat type I IGF receptors, and reacted specifically with the beta-subunit on immunoblots. Solubilized placental microsomal membranes were depleted of classical type I IGF receptors by incubation with an immobilized monoclonal antibody IGFR 24-55, which reacts well with type I receptors but very poorly with hybrid receptors. Residual hybrid receptors were then isolated by incubation with immobilized antibody IGFR 1-2, and recovered by elution with excess of synthetic peptide antigen. Binding properties of hybrids were compared with those of immuno-affinity-purified insulin receptors and type I IGF receptors, by using the radioligands 125I-IGF-I and 125I-insulin. Hybrids bound approx. 20 times as much 125I-IGF-I as 125I-insulin at tracer concentrations (approx. 0.1 nM). The binding of 125I-insulin, but not 125I-IGF-I, to hybrids increased after treatment with dithiothreitol to reduce disulphide bonds between the alpha-subunits. Hybrids behaved very similarly to type I receptors with respect to the inhibition of 125I-IGF-I binding by unlabelled IGF-I and insulin. By contrast, the affinity of hybrids for insulin was approx. 10-fold lower than that of classical insulin receptors, as assessed by inhibition of 125I-insulin binding by unlabelled hormone. It is concluded that the properties of insulin receptors, but not IGF receptors, are markedly affected by assembly as hybrid compared with classical structures, and that hybrids are more likely to be responsive to IGF-I than insulin under physiological conditions.

scholarly journals A single-chain insulin-like growth factor I/insulin hybrid binds with high affinity to the insulin receptor

1995 ◽  
Vol 305 (3) ◽  
pp. 981-986 ◽  
Author(s):  
C Kristensen ◽  
A S Andersen ◽  
M Hach ◽  
F C Wiberg ◽  
L Schäffer ◽  
...  
Keyword(s):  
Growth Factor ◽  
Insulin Receptor ◽  
Insulin Receptors ◽  
Insulin Like Growth Factor ◽  
Single Chain ◽  
Factor I ◽  
High Affinity ◽  
Igf I ◽  
Membrane Bound ◽  
Single Chain Insulin

1. To investigate the structure/function relationship of the interaction between ligand and receptor in the insulin-like growth factor I (IGF-I) and insulin receptor systems we have prepared and characterized a single-chain insulin/IGF-I hybrid. The single-chain hybrid consists of the insulin molecule combined with the C domain of IGF-I. The single-chain hybrid was found to bind with high affinity to both truncated soluble insulin receptors and membrane-bound holoreceptors. The affinity for interacting with the soluble truncated insulin receptors was 55-94% relative to insulin, and affinity for membrane-bound insulin receptors was 113% of that of insulin. Furthermore we found that the affinity of the single-chain hybrid molecule for IGF-I receptors was 19-28% relative to IGF-I. 2. The affinity of the single-chain hybrid for chimeric insulin/IGF-I receptors exceeded that of either natural ligand. This indicates that coordinately changing domains of the receptors and the ligands can induce higher affinity of ligand for receptor, supporting the idea that these receptors have a common ligand-binding site [Kjeldsen, Andersen, Wiberg, Rasmussen, Schäffer, Balschmidt, Møller and Møller (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 4404-4408]. 3. In contrast with what was generally assumed about the ligand structure required for binding to the insulin receptor we demonstrate the first single-chain insulin analogue that can bind with high affinity to the insulin receptor.

scholarly journals Insulin-like growth factor binding to the atypical insulin receptors of a human lymphoid-derived cell line (IM-9)

1990 ◽  
Vol 266 (3) ◽  
pp. 737-742 ◽  
Author(s):  
H A Jonas ◽  
A J Cox
Keyword(s):  
Growth Factor ◽  
Affinity Chromatography ◽  
Insulin Receptor ◽  
Binding Sites ◽  
Insulin Binding ◽  
Type I ◽  
Insulin Like Growth Factor ◽  
Igf Receptors ◽  
Type I Igf Receptor ◽  
Igf I

The cells of the IM-9 human lymphocyte-derived line contain a sub-population of insulin-binding sites whose immunological and hormone-binding characteristics closely resemble those of the atypical insulin-binding sites of human placenta. These binding sites, which have moderately high affinity for multiplication-stimulating activity [MSA, the rat homologue of insulin-like growth factor (IGF) II] and IGF-I, are identified on IM-9 cells by 125I-MSA binding. They account for approximately 30% of the total insulin-receptor population, and do not react with a monoclonal antibody to the type I IGF receptor (alpha IR-3). The relative concentrations of unlabelled insulin, MSA and IGF-I required to displace 50% of 125I-MSA from these binding sites (1:4.7:29 respectively) are maintained for cells, particulate membranes, Triton-solubilized membranes precipitated either by poly(ethylene glycol) or a polyclonal antibody (B-10) to the insulin receptor, and receptors purified by insulin affinity chromatography. Because the atypical insulin/MSA-binding sites outnumber the type I IGF receptors in IM-9 cells by approximately 10-fold, they also compete with the latter receptors for 125I-IGF-I binding. Thus 125I-IGF-I binding to IM-9 cells is inhibited by moderately low concentrations of insulin (relative potency ratios for insulin compared with IGF-I are approx. 1/14 to 1/4) and is partially displaced (65-80%) by alpha IR-3. When type I IGF receptors are blocked by alpha IR-3 or removed by B-10 immunoprecipitation or insulin affinity chromatography, the hormone-displacement patterns for 125I-IGF-I binding resemble those of the atypical insulin/MSA-binding sites.

scholarly journals Comparison of insulin-like growth factor I receptor and insulin receptor purified from human placental membranes.

1986 ◽  
Vol 261 (35) ◽  
pp. 16727-16731
Author(s):  
Y Fujita-Yamaguchi ◽  
T R LeBon ◽  
M Tsubokawa ◽  
W Henzel ◽  
S Kathuria ◽  
...  
Keyword(s):  
Growth Factor ◽  
Insulin Receptor ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Placental Membranes ◽  
Growth Factor I

Characterization of specific insulin-like growth factor (IGF)-I and IGF-II receptors on cultured rabbit articular chondrocyte membranes

1989 ◽  
Vol 120 (2) ◽  
pp. 245-249 ◽  
Author(s):  
J. Jansen ◽  
S. C. van Buul-Offers ◽  
C. M. Hoogerbrugge ◽  
T. L. de Poorter ◽  
M. T. Corvol ◽  
...  
Keyword(s):  
Growth Factor ◽  
Type I ◽  
Insulin Like Growth Factor ◽  
Articular Chondrocyte ◽  
Reducing Conditions ◽  
Receptor Sites ◽  
Igf I ◽  
Typical Type ◽  
Liver Membranes ◽  
Placental Membranes

ABSTRACT The interaction of insulin-like growth factor (IGF)-I and IGF-II with specific type-I and -II receptor sites on rabbit articular chondrocyte membranes was studied. With labelled IGF-I as tracer, half-maximal displacement of the label was obtained with 1·4 ng IGF-I/ml and 22 ng IGF-II/ml. Using IGF-II as labelled peptide, 16 ng unlabelled IGF-II/ml and 200 ng IGF-I/ml were needed to inhibit the binding by 50%. Covalent cross-linking experiments revealed the presence of typical type-I (Mr 130 000 under reducing conditions) and type-II (Mr 260 000) receptor sites. In addition, with 125I-labelled IGF-II a very intense labelled band appeared at Mr > 300 000. This band was not found in mouse liver membranes and human placental membranes. Journal of Endocrinology (1989) 120, 245–249

Upregulation of the Insulin Receptor and Type I Insulin-Like Growth Factor Receptor Are Early Events in Hepatocarcinogenesis

2011 ◽  
Vol 39 (3) ◽  
pp. 524-543 ◽  
Author(s):  
Eiman Aleem ◽  
Dirk Nehrbass ◽  
Fritz Klimek ◽  
Doris Mayer ◽  
Peter Bannasch
Keyword(s):  
Growth Factor ◽  
Insulin Receptor ◽  
Growth Factor Receptor ◽  
Type I ◽  
Insulin Like Growth Factor

scholarly journals Differential Activation of Insulin Receptor Substrates 1 and 2 by Insulin-Like Growth Factor-Activated Insulin Receptors

2007 ◽  
Vol 27 (10) ◽  
pp. 3569-3577 ◽  
Author(s):  
Adam Denley ◽  
Julie M. Carroll ◽  
Gemma V. Brierley ◽  
Leah Cosgrove ◽  
John Wallace ◽  
...  
Keyword(s):  
Growth Factor ◽  
Insulin Receptor ◽  
Splice Variants ◽  
Biological Effects ◽  
Insulin Receptors ◽  
Insulin Like Growth Factor ◽  
Extracellular Signal ◽  
Igf I ◽  
High Concentrations ◽  
Kinase Pathway

ABSTRACT The insulin-like growth factors (insulin-like growth factor I [IGF-I] and IGF-II) exert important effects on growth, development, and differentiation through the IGF-I receptor (IGF-IR) transmembrane tyrosine kinase. The insulin receptor (IR) is structurally related to the IGF-IR, and at high concentrations, the IGFs can also activate the IR, in spite of their generally low affinity for the latter. Two mechanisms that facilitate cross talk between the IGF ligands and the IR at physiological concentrations have been described. The first of these is the existence of an alternatively spliced IR variant that exhibits high affinity for IGF-II as well as for insulin. A second phenomenon is the ability of hybrid receptors comprised of IGF-IR and IR hemireceptors to bind IGFs, but not insulin. To date, however, direct activation of an IR holoreceptor by IGF-I at physiological levels has not been demonstrated. We have now found that IGF-I can function through both splice variants of the IR, in spite of low affinity, to specifically activate IRS-2 to levels similar to those seen with equivalent concentrations of insulin or IGF-II. The specific activation of IRS-2 by IGF-I through the IR does not result in activation of the extracellular signal-regulated kinase pathway but does induce delayed low-level activation of the phosphatidylinositol 3-kinase pathway and biological effects such as enhanced cell viability and protection from apoptosis. These findings suggest that IGF-I can function directly through the IR and that the observed effects of IGF-I on insulin sensitivity may be the result of direct facilitation of insulin action by IGF-I costimulation of the IR in insulin target tissues.

Sign in / Sign up

Export Citation Format

Share Document